SCHEMBL3790281

SCHEMBL3790281

CCOC(=O)c1ccc2c(c1)nc(Cl)c1cccn12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.51
KDM4E B2RXH2 2/20 0.51
LMNA P02545 1/20 0.51
HPGD P15428 1/20 0.51
SIRT2 Q8IXJ6 3/20 0.50
SIRT1 Q96EB6 3/20 0.50
NPC1 O15118 3/20 0.50
RAB9A P51151 2/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
PDE2A O00408 1/20 0.49
MAPT P10636 3/20 0.47
NPSR1 Q6W5P4 1/20 0.47
PTGER4 P35408 3/20 0.46
NLRP3 Q96P20 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
CSNK2A2 P19784 1/20 0.44
CSNK2B P67870 1/20 0.44
CSNK2A1 P68400 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29893072 0.86 KDM4E (0.50) KDM4ELMNANPC1RAB9AMAPT
SCHEMBL13056938 0.78 CSNK2A1 (0.57) ALDH1A1KDM4ELMNAHPGDSIRT2
SCHEMBL3784898 0.77 KDM4E (0.48) ALDH1A1KDM4EHPGDMEN1KMT2A
SCHEMBL31500068 0.77 CSNK2A1 (0.49) KDM4ECSNK2A2CSNK2BCSNK2A1HTT
SCHEMBL1458735 0.76 ALDH1A1 (0.58) ALDH1A1KDM4ELMNAHPGDSIRT2
SCHEMBL13082063 0.76 CSNK2A2 (0.54) ALDH1A1KDM4ELMNAHPGDSIRT2
SCHEMBL7400768 0.75 HTR3E (0.57) ALDH1A1KDM4EHPGDRAB9AKMT2A
SCHEMBL31377488 0.74 MAPT (0.43) ALDH1A1KDM4ELMNAHPGDSIRT2
SCHEMBL31377505 0.74 MAPT (0.43) ALDH1A1KDM4ELMNAHPGDSIRT2
SCHEMBL4471406 0.74 SIRT2 (0.71) ALDH1A1KDM4ELMNAHPGDSIRT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010135571-A1 NOVEL PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2010-11-25 WO disclosed
US-20100298302-A1 NOVEL PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2010-11-25 US disclosed
US-20100298302-A1 NOVEL PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2010-11-25 US disclosed
US-20100298302-A1 NOVEL PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2010-11-25 US disclosed
WO-2010135571-A1 NOVEL PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298302-A1 NOVEL PROTEIN KINASE MODULATORS PIM2, PIM1, PIM3 ALDH1A1 4648/4885KDM4E 1746/4885LMNA 4001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.